Advertisements

Адиуретин

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Адиуретин

Quick Facts

Property Description
Active ingredient Desmopressin (as Desmopressin acetate)
Form Tablets (oral/sublingual), Nasal Solution/Spray, Injection Solution
Pharmacological class Antidiuretic Hormone Analogue, Vasopressin Analogue
Common purpose Fluid balance control, reducing excessive urine output
Origin Synthetic Peptide

Defining Адиуретин: A Selective Vasopressin Analogue

Адиуретин is a prescription medication whose active substance is Desmopressin, officially categorized as an antidiuretic agent and a vasopressin analogue. This active ingredient is a synthetic peptide that is structurally derived from the body's natural hormone, arginine vasopressin (ADH). This specific chemical modification grants Desmopressin a high degree of selectivity, primarily stimulating V2 receptors in the kidneys. This key feature enables the drug to exhibit potent antidiuretic effects while substantially minimizing the pressor (blood pressure-raising) actions associated with the natural hormone.

Pharmaceutical Forms and General Purpose

The medication Адиуретин is a single active ingredient product offered in diverse pharmaceutical preparations to suit different patient needs and administration routes. These forms include standard oral tablets, fast-dissolving sublingual forms, nasal solutions (sprays or drops), and solution for injection. The medication's general purpose is to support the body's regulation of water by enhancing the kidneys' natural ability to achieve increased water reabsorption. By promoting the concentration of urine, the drug effectively reduces the volume of fluid passed, providing symptomatic relief in situations of excessive urinary output.

Advertisements

What side effects are possible with Адиуретин?

Possible Side Effects and Safety Information

The safety profile of Адиуретин (Desmopressin) is structured around its potent antidiuretic effect, as documented in official regulatory labeling (SmPC, FDA). Adverse reactions are classified by frequency and system-organ class.


Official Adverse Reaction Categories

Classification Examples of Reactions
Very Common (ge 1/10) Headache
Common (ge 1/100 to < 1/10) Nausea, Abdominal pain, Dizziness, Fatigue, Fluid retention, Hyponatremia
Uncommon Vomiting, Insomnia, Palpitations, Skin reactions

Serious Adverse Reactions and Safety Constraints

The most serious risk documented in regulatory warnings is severe hyponatremia (low blood sodium), caused by excessive water retention. Severe hyponatremia is associated with the potential for serious neurological events, including convulsions (seizures). Anaphylaxis is also documented as a rare, but serious, systemic allergic risk.


Contextual Safety Patterns

The risk of developing severe hyponatremia is explicitly noted in labeling as being highest during the first few days to one week of starting treatment or following a dosage increase. Furthermore, the official prescribing information includes population-specific safety considerations. Older adults have an increased risk of fluid retention and hyponatremia, and the medication is officially contraindicated in patients with moderate to severe renal impairment. All use requires explicit serum sodium monitoring to prevent and manage the risk of electrolyte imbalance, which is the defining safety constraint of the medicine.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Адиуретин (Desmopressin) states that overdose is primarily defined by the consequence of excessive antidiuretic effect, leading to water intoxication and the severe electrolyte imbalance of hyponatremia (low serum sodium concentration).

Documented Overdose Manifestations and Severe Outcomes

Category Official Regulatory Statements
Documented Overdose Presentations Symptoms may include headache, nausea, vomiting, confusion, drowsiness, and sudden weight gain [FDA Prescribing Information].
Physiological Systems Affected Primarily the Central Nervous System (CNS) and Electrolyte/Fluid Balance, with severe hyponatremia leading to convulsions and coma [EMA SmPC].
Population-Specific Overdose Notes Elderly patients are officially noted to be at an increased risk of severe hyponatremia and associated outcomes [FDA Prescribing Information].

Immediate Actions and Management

Regulatory authorities mandate that immediate medical attention must be sought for a suspected overdose, particularly if severe or life-threatening symptoms are present, such as seizures or loss of consciousness [MedlinePlus Drug Information].

Official Overdose Management Statements:

  • No specific antidote is known for Desmopressin overdose [NIH StatPearls].
  • Management focuses on symptomatic and supportive treatment [EMA SmPC].
  • Essential procedures include mandatory fluid restriction and careful correction of serum sodium levels [FDA Prescribing Information].
  • Continuous monitoring of serum electrolytes and fluid balance is required during overdose management [MHRA GOV.UK].

The resulting regulatory structure defines the overdose profile by linking excessive fluid retention directly to critical metabolic risk. This necessitates that users immediately seek help when symptoms of hyponatremia or water intoxication manifest.

Advertisements

Therapeutic Uses of Адиуретин

The core therapeutic applications of Адиуретин (Desmopressin) span three distinct domains. This medication is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms related to fluid balance, sleep disruption, and temporary bleeding management.

It is commonly used to address conditions characterized by systemic imbalance, including Central Diabetes Insipidus (CDI), Primary Nocturnal Enuresis (PNE) in children, Nocturia due to nocturnal polyuria in adults, and for supportive management of specific, mild to moderate inherited bleeding disorders, such as Hemophilia A and Type I Von Willebrand Disease.

For patients managing these conditions, the medication primarily helps address symptom clusters that interfere with daily functioning, offering symptomatic relief that helps patients cope more steadily. The goal is to provide supportive relief during symptomatic periods, whether that involves chronic hormone replacement or acute situational assistance in diverse clinical contexts.

Quick Fact: Relief for Disruptive Symptoms
Primary Focus: Is used for managing excessive fluid output and preventing related nocturnal voiding episodes.
Patient Benefit: Contributes to easing the overall symptom load related to chronic thirst, polyuria, and disrupted sleep.
Contextual Use: Applied in clinical settings that involve acute or unstable symptom patterns, such as situational bleeding risk or chronic hormone deficiency.
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Адиуретин?

The population eligibility for Адиуретин (Desmopressin) is strictly defined by regulatory authorities to prevent the serious risk of hyponatremia (low sodium levels). The official labeling identifies groups for whom use is permitted, restricted, or absolutely prohibited (contraindicated).

Populations Who Must Not Use the Medicine (Contraindications):

Contraindicated Condition Regulatory Basis
Hyponatremia or history of low sodium levels Absolute Prohibition
Moderate to Severe Renal Impairment (eGFR/CrCl < 50 mL/min) Absolute Prohibition
NYHA Class II-IV Congestive Heart Failure Absolute Prohibition
Acute illness with electrolyte imbalance Temporary Prohibition
Known Hypersensitivity to the drug substance Absolute Prohibition

Age and Specific Restrictions:

Use is not recommended for the treatment of nocturia or enuresis in older adults (≥ 65 years). In pediatric patients, there are minimum age thresholds: it is not established for Central Diabetes Insipidus (CDI) in children under 4 years or for Primary Nocturnal Enuresis (PNE) in children under 6 years. All eligible patients, including children, must adhere to strict fluid restriction protocols. Regulatory documents also advise caution for use during pregnancy (Category B) and lactation, permitting use only if clearly needed.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Адиуретин (Desmopressin) is structured around two primary categories of documented interactions: pharmacodynamic effects and exposure modifications. The most critical interactions are pharmacodynamic, primarily affecting fluid and electrolyte balance due to the drug's antidiuretic action.


Documented Pharmacodynamic Interactions

Classification Interacting Agents Official Restriction/Outcome
Contraindicated Combinations Loop Diuretics, Systemic Glucocorticoids Co-administration is formally prohibited due to a high risk of severe hyponatremia.
Increased Hyponatremia Risk SSRIs, Tricyclic Antidepressants, NSAIDs, Carbamazepine, Opiate Analgesics Requires close and frequent monitoring of serum sodium levels.
Additive Pressor Activity Other Vasoconstrictor Agents May be associated with a slight elevation of blood pressure.

Exposure Modification and Timing Rules

The absorption of Адиуретин is susceptible to external factors. For oral and sublingual forms, the ingestion of food is documented to reduce and delay the extent of the drug's systemic exposure. This pharmacokinetic interaction necessitates a mandatory fluid intake restriction from one hour before until eight hours after administration of the sublingual formulation. Furthermore, the use of other intranasal agents may alter the nasal mucosa, which can potentially lead to unreliable absorption of the nasal spray product.

Advertisements

Mechanism of Action

Selective V2 Receptor Activation in the Kidney

The primary action of Desmopressin is the selective agonism of the Vasopressin V2 Receptor ( V2 R) found on renal cells. This molecular specificity results in minimal activation of the V1 a receptors, which are responsible for widespread vasoconstriction, thereby focusing action on the antidiuretic pathway.


Intracellular Cascade and Water Channel Translocation

Activation of the V2 R triggers an intracellular signaling cascade involving cAMP and PKA, which culminates in the translocation of pre-formed Aquaporin-2 ( AQP-2) water channels to the kidney cell membrane. This mechanism increases the water permeability of the collecting ducts, which facilitates water reabsorption down the osmotic gradient.


Resulting Fluid Balance Modulation

This enhanced permeability and water reabsorption is the ultimate physiological consequence of the mechanism, resulting in a reduction in the volume of urine produced and a corresponding increase in its concentration (osmolality). This action modulates renal water balance, contributing to the conservation of fluid volume.


Mechanistic Constraint in Receptor Insensitivity

The mechanism is constrained by the functionality of the V2 R system; if the receptor or its downstream components are defective, such as in states of receptor insensitivity, the agonist signal cannot be processed, and the water reabsorption effect is minimal or absent.

Advertisements

Dosage and Administration Information

How to Use Адиуретин (Desmopressin)

Administration of Адиуретин follows standard protocols that vary depending on the route and the condition being managed. The medication is available for administration via four main routes: oral (tablets or sublingual lyophilisates), intranasal (spray or solution), intravenous (IV) injection, and subcutaneous (SC) injection.

Dosing and Frequency

Dosing is titrated (individually adjusted) to the lowest effective amount necessary to achieve the desired response. For chronic conditions such as Central Diabetes Insipidus (CDI), the oral starting dose is typically 0.05 mg twice daily, with the total daily dose divided and adjusted separately to maintain adequate water turnover. For nocturnal conditions like Primary Nocturnal Enuresis, the medication is taken once daily at bedtime.

Required Procedural Conditions

Administration involves adherence to specific protocols:

  • Fluid Restriction: For antidiuretic uses (CDI, nocturnal voiding), the protocol includes strict fluid intake restriction starting 1 hour before the evening dose until at least 8 hours after administration to mitigate the risk of water imbalance.
  • Intravenous Use: When used for hemostasis (e.g., Hemophilia A), the dose is diluted in 0.9% Sodium Chloride and administered as a slow infusion over 15 to 30 minutes. Repeat doses for this purpose are typically restricted to no more frequently than every 48 hours.
  • Missed Dosing: If a scheduled dose is missed, standard practice is not to take a double dose at the next scheduled time.

Administration Summary

Administration Route Frequency Pattern Key Constraint
Oral (Tablet/Sublingual) Daily (Once or Divided) Mandatory fluid restriction
IV Injection (Hemostasis) As-needed/Intermittent Dilution and slow 15 - 30 minute infusion
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Адиуретин (Desmopressin)

The research into the clinical application of Адиуретин (Desmopressin) focuses on its action on fluid concentration across several specific health conditions. The following overview describes the types of research conducted, the outcomes that were measured, and the existing limitations, based on governmental and peer-reviewed scientific sources.


Evidence for Use in Central Diabetes Insipidus (CDI)

Research exploring how symptoms change over time in Central Diabetes Insipidus has largely relied on long-term management studies and observational settings evaluating daily-life functioning. Desmopressin was studied for its use in the study of fluid balance and excessive urine output in individuals with AVP deficiency. Studies monitored physiological strain and reported how symptoms evolved, consistent with research exploring action on fluid concentration.

Because this is a long-standing therapeutic agent, initial confirmatory studies against a placebo are less common in recent literature. Research continues to explore factors that influence long-term dose stability in these patient cohorts.


Evidence for Use in Primary Nocturnal Enuresis (PNE) and Nocturia

For Primary Nocturnal Enuresis (PNE) and nocturia, research focused on short-term Randomized Controlled Trials (RCTs). These trials explored outcomes related to sleep disruption and physical discomfort, specifically monitoring the change in the frequency of wet nights per week (PNE) or nocturnal voiding episodes (nocturia).

RCTs reported patterns observed in the studies compared to placebo. However, the follow-up durations were limited (typically 4 to 12 weeks), and research highlights changes measured only during the study period. A key limitation noted in research is that findings describe group patterns, not personal outcomes, and evidence suggests that symptoms often return after treatment is stopped for PNE.


What is Still Uncertain About Адиуретин

Comparative evidence is often lacking against specific alternative treatments. Sample sizes were modest in some trials, and follow-up durations were limited for PNE and nocturia, meaning long-term effects are not fully established in these contexts. The studied profile of the medication reflects the specific conditions under which studies were conducted, and findings reflect group patterns, not personal outcomes. Research continues to explore the variability in individual response.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Адиуретин (FAQ)

Q: How long does the effect of Адиуретин typically last?

Regulatory documents state that the antidiuretic effect, which helps control fluid balance, typically begins within one hour after administration. This effect may last for 10 to 12 hours. This duration is a factor considered when establishing dosing schedules for various conditions.

Q: Are there any specific food items to be cautious about when taking Адиуретин?

Official instructions indicate that, specifically for nocturnal conditions, caffeine intake from sources such as coffee, tea, cola, or energy drinks should be avoided before bedtime. These substances can potentially impact the drug's intended action on fluid balance.

Q: Is Адиуретин safe to use for older adults (seniors)?

Official prescribing information indicates that older adults are generally at a higher risk of toxic reactions because they are more likely to have decreased kidney function. Due to the increased risk of fluid retention and low sodium levels (hyponatremia) in this population, regulatory guidance advises careful dose selection. Periodic monitoring of kidney function may be useful during treatment.

Q: Can a person with a history of seizures use Адиуретин?

Official documents state that the medication is formally contraindicated (prohibited) in patients who currently have or have a history of low sodium levels (hyponatremia). This is because severe hyponatremia is a serious safety concern that is associated with the potential for serious neurological events, including seizures.

Q: What is the official safety classification of Адиуретин (e.g., Pregnancy Category)?

According to official regulatory bodies, Адиуретин is a prescription-only drug (Rx-only) and is not listed as a federally controlled substance. While its status is not that of a controlled substance, official information does assign it a Pregnancy Category, such as Category B in certain regions.

Q: How often are blood tests usually recommended while taking Адиуретин?

Regulatory information emphasizes the need for regular monitoring of serum sodium concentration due to the risk of hyponatremia. Blood tests are typically required within the first week of starting or resuming the medication and again approximately one month after initiation. Testing is also required periodically thereafter, or following a dose adjustment.

Q: Is the nasal spray version of Адиуретин generally considered more or less effective than the tablets?

The medication is manufactured in several forms, including oral tablets and nasal solutions. Official regulatory documents do not contain a general statement comparing the relative effectiveness of the nasal versus oral formulations. The choice of which form to use is generally based on the specific condition being treated and the patient’s individual response.

Q: Are there any warnings about driving or operating machinery while taking Адиуретин?

Official warnings indicate that, due to potential side effects such as dizziness or confusion, activities requiring full mental alertness, such as driving or operating machinery, should be approached with caution. These symptoms are often related to low sodium levels.

Q: How quickly does Адиуретин generally start to work after taking it?

Regulatory documents state that the antidiuretic effect, which is the primary intended action on fluid balance, typically begins within one hour after administration.

Q: Is it common for people to experience temporary changes in thirst when using Адиуретин?

The medication is primarily designed to decrease excessive thirst associated with certain conditions. However, regulatory post-marketing reports note that increased thirst has been reported as a rare adverse reaction.

Q: Does drinking alcohol affect how Адиуретин works?

Official product information notes specific warnings against the use of alcohol before bedtime, particularly when the medication is taken for nocturnal conditions. This warning is based on the potential for alcohol to impact the medication's effects on fluid balance.

Q: What are the guidelines for discontinuing Адиуретин use?

Regulatory documents state that treatment discontinuation may be required immediately if symptoms signaling potential low sodium (hyponatremia) occur, such as a severe headache, nausea, or vomiting. The decision for temporary or permanent discontinuation is based on the severity of the symptoms and clinical circumstances.

Q: What happens if someone accidentally takes too much Адиуретин?

Symptoms reported in cases of accidental overdose can include confusion, headache, drowsiness, sudden weight gain, and difficulty urinating. Official guidance regarding overdose symptoms states that emergency medical services must be contacted immediately if an overdose is suspected.

Q: Is Адиуретин a controlled substance?

Official regulatory classification states that Адиуретин is a prescription-only drug (Rx-only). It is not listed as a federally controlled substance in major regulatory jurisdictions.

Q: Does Адиуретин cause weight gain or weight loss?

Fluid retention or sudden weight gain is a documented side effect, which is often associated with the medication’s primary action on water retention or the occurrence of low sodium levels (hyponatremia).

Q: Is Адиуретин known to cause changes in mood or anxiety?

Official adverse event reports indicate that mental or mood changes, including confusion, irritability, and restlessness, have been reported as side effects. These psychological changes are often associated with low sodium levels in the blood (hyponatremia).

Q: What if I have an allergic reaction to Адиуретин?

Official information states that due to the potential for rare, severe allergic reactions (anaphylaxis), emergency medical services should be contacted immediately if symptoms like rash, swelling of the throat or face, or trouble breathing occur.

Advertisements

How should Адиуретин be stored and disposed of?

How to Store and Dispose of Адиуретин ( Desmopressin)

Official regulations require specific storage conditions for Адиуретин based on its form. Oral tablets must be stored at Controlled Room Temperature (20 C to 25 C) and kept protected from excessive heat or light. Liquid nasal solutions must be refrigerated (2 C to 8 C) and should not be frozen.

All forms must be kept in the original container, tightly closed, and stored strictly out of the sight and reach of children.

Specific products have stability limits: some nasal sprays must be discarded 4 weeks after first opening or after a certain number of doses. For disposal, any unused product or waste material must be handled in accordance with local requirements and must not be placed in household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Адиуретин found in:

A-Z Index: